BioNexus Gene Lab Statistics
Total Valuation
BGLC has a market cap or net worth of $3.85 million. The enterprise value is $647,853.
| Market Cap | 3.85M |
| Enterprise Value | 647,853 |
Important Dates
The last earnings date was Friday, August 14, 2026, after market close.
| Earnings Date | Aug 14, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
BGLC has 2.42 million shares outstanding. The number of shares has increased by 20.61% in one year.
| Current Share Class | 2.42M |
| Shares Outstanding | 2.42M |
| Shares Change (YoY) | +20.61% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 48.66% |
| Owned by Institutions (%) | 0.69% |
| Float | 848,760 |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.21 |
| Forward PS | n/a |
| PB Ratio | 0.49 |
| P/TBV Ratio | 0.49 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.19 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.08, with a Debt / Equity ratio of 0.04.
| Current Ratio | 6.08 |
| Quick Ratio | 4.56 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -163.17 |
Financial Efficiency
Return on equity (ROE) is -33.66% and return on invested capital (ROIC) is -60.88%.
| Return on Equity (ROE) | -33.66% |
| Return on Assets (ROA) | -18.99% |
| Return on Invested Capital (ROIC) | -60.88% |
| Return on Capital Employed (ROCE) | -34.83% |
| Weighted Average Cost of Capital (WACC) | 15.33% |
| Revenue Per Employee | $164,557 |
| Profits Per Employee | -$135,533 |
| Employee Count | 19 |
| Asset Turnover | 0.34 |
| Inventory Turnover | 2.93 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -65.36% in the last 52 weeks. The beta is 2.19, so BGLC's price volatility has been higher than the market average.
| Beta (5Y) | 2.19 |
| 52-Week Price Change | -65.36% |
| 50-Day Moving Average | 1.84 |
| 200-Day Moving Average | 2.79 |
| Relative Strength Index (RSI) | 60.85 |
| Average Volume (20 Days) | 16,871 |
Short Selling Information
The latest short interest is 6,424, so 0.27% of the outstanding shares have been sold short.
| Short Interest | 6,424 |
| Short Previous Month | 3,503 |
| Short % of Shares Out | 0.27% |
| Short % of Float | 0.76% |
| Short Ratio (days to cover) | 0.66 |
Income Statement
In the last 12 months, BGLC had revenue of $3.13 million and -$2.58 million in losses. Loss per share was -$1.19.
| Revenue | 3.13M |
| Gross Profit | 385,894 |
| Operating Income | -2.76M |
| Pretax Income | -2.58M |
| Net Income | -2.58M |
| EBITDA | -2.64M |
| EBIT | -2.76M |
| Loss Per Share | -$1.19 |
Balance Sheet
The company has $3.52 million in cash and $323,197 in debt, with a net cash position of $3.20 million or $1.32 per share.
| Cash & Cash Equivalents | 3.52M |
| Total Debt | 323,197 |
| Net Cash | 3.20M |
| Net Cash Per Share | $1.32 |
| Equity (Book Value) | 7.78M |
| Book Value Per Share | 3.22 |
| Working Capital | 4.13M |
Cash Flow
In the last 12 months, operating cash flow was -$846,565 and capital expenditures -$7,035, giving a free cash flow of -$853,600.
| Operating Cash Flow | -846,565 |
| Capital Expenditures | -7,035 |
| Depreciation & Amortization | 116,512 |
| Net Borrowing | 107,006 |
| Free Cash Flow | -853,600 |
| FCF Per Share | -$0.35 |
Margins
Gross margin is 12.34%, with operating and profit margins of -88.16% and -82.36%.
| Gross Margin | 12.34% |
| Operating Margin | -88.16% |
| Pretax Margin | -82.36% |
| Profit Margin | -82.36% |
| EBITDA Margin | -84.44% |
| EBIT Margin | -88.16% |
| FCF Margin | n/a |
Dividends & Yields
BGLC does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -20.61% |
| Shareholder Yield | -20.61% |
| Earnings Yield | -67.85% |
| FCF Yield | -22.49% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on April 7, 2025. It was a reverse split with a ratio of 1:10.
| Last Split Date | Apr 7, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |